Tesla stock declined 0.2% to $391.59 on Tuesday ahead of Q1 earnings due Wednesday. Wall Street analysts are divided, with Jefferies raising its price target to $350 but maintaining a Hold rating, citing execution concerns, while Bank of America kept a $460 target. Analysts expect Tesla to report an EPS of $0.36 on $22.3 billion revenue.
Cardano (ADA) is trading at $0.25, with potential to reclaim $0.30 as CME futures volumes surge. The recent price rise aligns with increased futures activity over the past three days, indicating growing investor interest. Analysts suggest that rising futures volumes could support further price recovery for ADA in the coming weeks.
Crypto analyst Trader Tardigrade predicts Dogecoin could rally 3,000% to $4, driven by a bullish setup and an inverse head and shoulders pattern. The analyst highlights fading selling pressure and bullish divergence signals, suggesting a potential trend reversal. If confirmed, this move could mirror the 2017 rally, where DOGE surged from $0.00017 to $0.005.
Palantir (PLTR) stock, down 18% year-to-date, received a boost after Trump praised its “war fighting capabilities,” but Wall Street remains skeptical due to high valuation concerns. The company reported Q4 earnings of $0.25 EPS on $1.41 billion revenue, a 70% increase year-over-year. Despite strong earnings, PLTR trades at a P/E ratio over 231, with a 200-day moving average of $164.55.
Seagate Technology (STX) reached an all-time high of $554.21, with a 1-year return of 639.49%, and a market cap of $123.3 billion. The company's revenue grew 25%, and BofA projects Q3 FY2026 revenue of $3.02 billion and EPS of $3.70, surpassing analyst estimates. Seagate also announced the sale of its Lyve Cloud storage business to Wasabi.
Arrowhead Pharma (ARWR) stock has surged 481% over the past year, with analysts predicting further gains. Morgan Stanley upgraded ARWR to Overweight with a $100 price target, citing upcoming Phase 3 data for the drug plozasiran, expected in Q3 2026. BofA also raised its price target, estimating a peak market of around $3 billion for the drug.
Intel (INTC) stock received three analyst upgrades on April 21, 2026. BNP Paribas upgraded it from Underperform to Neutral with a $60 target, HSBC raised its rating to Buy with a $95 target, and KeyBanc rated it Overweight with a $70 target. The upgrades reflect optimism over server CPU momentum and a potential cyclical recovery.